help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costa, A. P. R.
Right arrow Articles by Dos Reis, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costa, A. P. R.
Right arrow Articles by Dos Reis, A. M.
Endocrinology Vol. 144, No. 5 1942-1948
Copyright © 2003 by The Endocrine Society

Angiotensin-(1–7): A Novel Peptide in the Ovary

Amilton P. R. Costa, Christiane R. Fagundes-Moura, Virginia M. Pereira, Leonardo F. Silva, M. Aparecida R. Vieira, Robson A. S. Santos and Adelina M. Dos Reis

Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, 31270-901 Belo Horizonte, Brazil

Address all correspondence and requests for reprints to: Dr. Adelina Martha dos Reis, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Antonio Carlos 6627, CEP 31270–901, Belo Horizonte MG, Brazil. E-mail: adelina{at}icb.ufmg.br.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The present study was undertaken to investigate the presence of angiotensin-(1–7) [Ang-(1–7)] in the ovary and a possible role for it. Cycling female rats were killed in each phase of the estrous cycle, and ovarian Ang II and Ang-(1–7) were separated by HPLC and measured by RIA. The mean levels of Ang-(1–7) in proestrus and estrus were significantly higher than those in metestrus and diestrus (P < 0.05). Ang-(1–7) was also significantly higher in equine chorionic gonadotropin (eCG)-treated immature rats. Ang-(1–7) induced a significant increase in estradiol and progesterone production (P < 0.05) in the ovary of immature rats (24–25 d old) pretreated with eCG and perfused in a closed circuit system. This effect was blocked by A-779, a specific Ang-(1–7) antagonist (P < 0.05). The present data demonstrate the presence and physiological role of a novel renin-Ang system peptide in the ovary. The higher level of Ang-(1–7) in proestrus and estrus as well as in eCG-treated rats suggests the involvement of this renin-Ang system peptide in pre- and postovulatory events.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
THE IDENTIFICATION of prorenin, renin, angiotensinogen, angiotensin-converting enzyme (ACE), angiotensin II (Ang II), and Ang II receptors in the ovary suggests that there is a functional ovarian renin-Ang system (RAS). It may play a significant role in several areas of ovarian physiology, such as follicular development, steroidogenesis, oocyte maturation, ovulation, and follicular atresia (reviewed by in Ref. 1). Nonetheless, most studies of ovarian RAS have been performed in rodents (1), a number of relevant experiments have also been carried out in bovines and humans (2, 3), and functional roles for ovarian RAS in development, ovulation, and luteal function have been suggested (3). Disturbances in the ovarian RAS can be the cause or the consequence of serious reproductive disorders, such as polycystic ovary syndrome and ovarian hyperstimulation syndrome (4, 5, 6, 7).

However, despite the large number of studies of ovarian RAS, understanding of the physiological role of Ang II in some events has been impaired by discrepant findings. Saralasin, a nonspecific Ang receptor antagonist, blocked ovulation in immature rats treated with equine chorionic gonadotropin (eCG) and human chorionic gonadotropin (hCG) (8) and inhibited hCG-induced ovulation in rabbit ovaries perfused in vitro (9, 10). In contrast, an autoradiographic study demonstrated the presence of great number of Ang II receptors in atretic follicles (11), but not in preovulatory follicles containing LH receptors (12). Similarly, inhibition of Ang II production using captopril, an ACE inhibitor, did not affect ovulation in immature rats in which ovulation was induced with eCG and hCG or in perfused rabbit ovaries, suggesting that locally produced Ang II is not essential for processes that affect ovulation (13, 14, 15). Potential mechanisms for explaining the lack of a captopril effect on ovulation include the generation of other Ang fragments and different pathways for Ang II production without ACE participation. Ang-(1–7), a biologically active member of the RAS that can be formed by an ACE-independent pathway, could play a role in ovulation and ovarian regulation. This Ang is the most pleiotropic of the Ang II derivatives, producing effects similar to, opposite from, or distinct from those of Ang II [reviewed by Santos et al. (16)]. Ang-(1–7) can be generated by processing of Ang I by endopeptidases (NEP 24.11 and prolyl-endopeptidase) or of Ang II by prolyl-endopeptidase or prolyl-carboxy-peptidase and ACE-2 [reviewed by Santos et al. (17)]. Although a specific receptor for Ang-(1–7) has not yet been cloned, evidence is accumulating for the existence of a selective Ang-(1–7) receptor, especially after the availability of its selective antagonist D-Ala7-Ang-(1–7) (A-779; Ref. 18).

The purpose of this study was to determine the presence of Ang-(1–7) and its possible physiological role in the ovary. Our results show that Ang-(1–7) is present in the rat ovary, that its concentrations vary during the estrous cycle, and that it induces estrogen production in perfused ovaries of eCG-treated rats.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
Female Wistar rats obtained from CEBIO-UFMG (Belo Horizonte, Brazil) were cared for according to the international guidelines for animal care. The experimental protocol was approved by the ethics committee in animal experimentation of Federal University of Minas Gerais. The animals (four or five per cage) were maintained under controlled light and temperature conditions (lights on from 0500–1900 h; 23 ± 3 C) and had free access to tap water and a standard rat chow (Nuvital Nutrientes Ltd., Colombo, Brazil). For determination of Angs in the ovaries, adult rats, weighing 220–250 g, were used. After at least three consecutive regular estrous cycles, the animals were killed by decapitation between 1000–1100 h, and the ovaries were pooled into four groups according to the cycle phase. Immature rats (24–25 d old) injected sc with eCG (20 IU in 0.2 ml; Sigma-Aldrich Corp., St. Louis, MO) 48 h before the experiments were used for ovarian Ang-(1–7) determination and for ovarian perfusion experiments.

Ovarian processing for determination of Ang concentrations in rat ovaries
After decapitation, the ovaries were immediately removed, cleaned of fat, frozen in liquid nitrogen, and stored at -80 C until processing. Pairs of ovaries were then homogenized in 0.1 N acetic acid solution containing the following protease inhibitors: 10-5 M phenylmethylsulfonylfluoride, 10-5 M pepstatin A, 10-5 M EDTA, 10-5 M p-hydroxymercuribenzoate, and 9 x 10-4 M orthophenanthroline, all purchased from Sigma-Aldrich Corp. After centrifugation (20,000 x g, 4 C, 30 min), peptides were extracted using Sep-Pak C18 cartridges (Waters Corp., Milford, MA) activated by sequential washes with acetonitrile and ammonium acetate (pH 4) and eluted with acetonitrile/ammonium acetate solution (99:1). The samples were dried in a SpeedVac (Eppendorf concentrator, Hamburg, Germany) apparatus and stored at -80 C until processing.

Determination of ovarian Ang
Ang peptides were analyzed by a combination of HPLC and RIA (19, 20, 21, 22). HPLC was performed on a Shimatzu HPLC system (Shimatzu Co., Kyoto, Japan) equipped with two LC-9A pumps controlled by a SCL-6B system controller, an SPD-6A UV-Vis spectrophotometric detector, and a C-R6A chromatopic integrator. Reverse separation was carried out using a Vydac RP-18 column (25 x 0.46 cm; particle size, 5 µm; Vydac, Hesperia, CA) coupled to a Vydac guard column. Gradient elution was obtained with aqueous 0.13% Hepta-fluor-butiric acid (mobile phase A) and 0.13% Hepta-fluor-butiric acid/80% acetonitrile in water (mobile phase B). Gradient conditions were 30–45% mobile phase B, in 40 min, 62–90% B from 50–60 min, 100% B from 62–64 min, and 62% to 30% B from 65–70 min at a flow rate of 1.0 ml/min. Samples were collected every 30 sec and evaporated in a vacuum centrifuge (Eppendorf, Brinkmann Instruments, Inc., West Orange, NY) before RIA. Calibration of the system was achieved by injection of cold synthetic Angs and Ang fragments or 125I-labeled Angs, with each sample monitored by a {gamma}-counter or assayed by RIA. HPLC fractions 1–32 were assayed for Ang-(1–7) immunoreactivity (-ir), fractions 33–62 were processed for Ang II-ir, and fractions 63–95 were assayed for Ang I-ir. The HPLC grade solvents were obtained from Merck \|[amp ]\| Co., Inc. (Darmstadt, Germany). The standard Ang peptides were purchased from Bachem (Torrance, CA).

Calibration of the HPLC column, using a mixture of synthetic standards, revealed a clearly defined sequence of the retention times. For detection of different peptides, three specific antibodies were used: one for Ang-(1–7); one that recognizes Ang-(4–8), Ang-(3–8), Ang II, and Ang-(2–8); and one that recognizes Ang-(3–10), Ang-(4–10), Ang I, and Ang-(2–10). Figure 1Go shows that under our conditions these peptides were resolved as clearly identifiable peaks.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 1. Chromatographic separation of a mixture of synthetic Ang peptides by reverse phase HPLC (see text for chromatographic conditions). The mixture of peptides was fractionated by HPLC and detected by RIA. Three different antibodies were used for measurement of the peptides by RIA: one for Ang-(1–7); another for Ang-(4–8), Ang-(3–8), Ang II, and Ang-(2–8); and another for Ang-(4–10), Ang I, and Ang-(2–10).

 
The chromatographic profile of the Angs [Ang I, Ang II, and Ang-(1–7)] was determined in pools of rat ovaries in each phase of the estrous cycle. To ensure the detectability of peptides, ovaries from four to seven rats were pooled. The samples were corrected per gram of tissue, and statistics were performed using the total number of pools.

Ovarian perfusion
The surgical procedure for rat ovary isolation was previously described by Koos et al. (23). Although the details of the standard perfusion system have been modified, the basic components have remained constant. The immature rats were anesthetized with sodium pentobarbital (30 mg/kg) and received 500 IU/100 g heparin sulfate, ip (Liquemine, Roche, Rio de Janeiro, Brazil). After laparotomy, the aorta artery was cannulated close to the right ovarian artery bifurcation. All branches of the aorta and vena cava were ligated and severed. The right uterus-ovarian artery, vein, and tip of the uterine horn were doubly ligated en masse just adjacent to the ovary and oviduct and severed. Aorta and vena cava were ligated en masse near the bifurcation and severed. The right ovary preparation was then removed from the animal and perfused with cold saline solution to completely wash out blood. Finally, the ovarian preparation was attached to the perfusion apparatus via the aortic cannula.

The perfusion system was similar to that described by Brännström et al. (24) and consisted of a closed system in which the medium recirculates. The medium consisted of 40 ml medium 199 with Earle’s salt, L-glutamine (Sigma-Aldrich Corp.) supplemented with 4% BSA (Sigma-Aldrich Corp.), 18 mM HEPES (Sigma-Aldrich Corp.), 0.02 µg/ml insulin (Biohulin, Biobras, Montes Claros, Brazil), 0.2 µg/ml heparin sulfate (Liquemine Roche), and 60 µg/ml gentamicin sulfate (Garamicina, Schering, Rio de Janeiro, Brazil). Temperature (37 C), pH (7.4), pressure (80 mm Hg), and oxygenation (95% O2/5% CO2) were maintained constant (modified from Ref. 23). All tubes and glass components of the perfusion system were siliconized to avoid steroid adherence to the walls.

Samples of perfusion medium (1.8 ml) were taken at 0, 1, 2, 3, 4, 6, 8, and 10 h after the 1-h stabilization period. The peptides, Ang II (1 µM), Ang-(1–7) (1 µM), and A-779 (1 µM) were added to the perfusion medium immediately after the first sample collection (0 h). The volume removed was replaced with the same volume of fresh medium containing the peptide. Samples were frozen at -20 C until processing.

Estradiol and progesterone RIA
Estradiol and progesterone concentrations in the perfusion medium were determined by RIA. After extraction with ethyl ether, the perfusion medium was dried and reconstituted in assay buffer. Estradiol and progesterone antibodies produced in rabbits and donated by Dr. José Antunes Rodrigues (FMRP-USP, Ribeirão Preto, Brazil) were used for RIA. Estradiol and progesterone standards (purchased from Sigma-Aldrich Corp.) and [3H]estradiol and [3H]progesterone (Amersham Pharmacia Biotech, Arlington Heights, IL) were used. Separation was performed with 200 µl of a suspension consisting of 625 mg activated charcoal (Merck \|[amp ]\| Co., Inc.) and 62.5 mg dextran (D-1537, Sigma-Aldrich Corp.) in gel/0.1% phosphate buffer. The radioactivity was counted in a scintillation analyzer ß-counter (TR-1600, Packard Instrument Co., Meridian, NJ), using a scintillation cocktail consisting of 5 g 2,5-diphenyloxazole (Merck \|[amp ]\| Co., Inc.) and 625 mg 1,4-bis[5-phenyl-2-oxazolyl]benzene/2,2'-p-phenylene-bis[5-phenyloxazole] (Sigma-Aldrich Corp.) in toluene/methanol (980/20 ml; Merck \|[amp ]\| Co., Inc.).

Statistical analysis
Data were expressed as the mean ± SEM. Ovarian Ang concentrations were analyzed by the Kruskal-Wallis test. Estradiol and progesterone concentrations in the perfusion medium were analyzed by two-way ANOVA, followed by the Newman-Keuls test. Comparisons with P < 0.05 were considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Ang-(1–7), Ang II, and Ang I levels in rat ovary
Figure 2Go displays a representative reverse phase HPLC profile of ovarian Ang-(1–7), Ang II, and Ang I immunoreactivity during different phases of the rat estrous cycle. Three distinct peaks were identified by specific antibodies for Ang-(1–7), Ang II, and Ang I, respectively. Ovarian levels of Ang-(1–7) were higher in proestrus (Fig. 2AGo) and estrus (Fig. 2BGo) than in metestrus (Fig. 2CGo) and diestrus (Fig. 2DGo). The ovarian levels of Ang II were higher in proestrus, lower in metestrus and diestrus, and undetectable in estrus in this particular experiment. Ang I-ir was present in all estrous cycle phases.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 2. Representative reverse phase HPLC profile of ovarian Ang-(1–7), Ang II, and Ang I-ir during different phases of the rat estrous cycle (A, proestrus; B, estrus; C, metestrus; D, diestrus). Three distinct peaks were identified by specific antibodies for Ang-(1–7), Ang II, and Ang I, respectively.

 
The averaged values of three different pools (Fig. 3AGo) show that ovarian Ang-(1–7) concentrations in proestrus (115.3 ± 77.3 pg/g ovary) and estrus (62.8 ± 28.3 pg/g ovary) were significantly higher (P < 0.05) than in the other phases of the estrous cycle (metestrus, 8.3 ± 7.3; diestrus, 7.2 ± 6.2 pg/g ovary). Higher concentrations of Ang-(1–7) were also observed in eCG-treated rats (142 ± 32 pg/g ovary; n = 2 pools), and undetectable levels were observed in immature rats.



View larger version (13K):
[in this window]
[in a new window]
  		Figure 3. Concentrations of Ang-(1–7) (A) and Ang II (B) in rat ovary in different phases of estrous cycle. The data show the mean ± SEM of three pools of ovaries in each phase of the estrous cycle. Ang-(1–7) and Ang II were measured by RIA after HPLC processing. Different letters denote statistically different values (P < 0.05).

 
Ang II levels (Fig. 3BGo) in proestrus (122.4 ± 53.0 pg/g ovary) were about 10-fold higher than those in all other phases of the cycle (estrous, 10.8 ± 5.1; metestrus, 8.4 ± 7.4; diestrus, 12.3 ± 5.7 pg/g ovary). No statistical difference was observed for Ang I (data not shown).

Isolated perfused ovaries
The physiological role of Ang-(1–7) was tested using perfused ovaries of immature rats pretreated with eCG. Ang-(1–7) 10-6 M induced a significant increase in estradiol (Fig. 4AGo) and progesterone (Fig. 5AGo) production starting at the first hour and increasing up to the sixth hour of perfusion. The effect of Ang II (Figs. 4BGo and 5BGo) was similar to that of Ang-(1–7).



View larger version (16K):
[in this window]
[in a new window]
  		Figure 4. Effects of Ang-(1–7) (A) and Ang II (B) on estradiol production by perfused rat ovary. Ovaries of immature rats pretreated 48 h previously with eCG (20 IU) were perfused with medium alone, 1 µM Ang-(1–7), 1 µM Ang II, or a combination of Ang-(1–7) and A-779 (A) or Ang II and A-779 (B). Data points show the mean ± SEM of six or seven ovary perfusions. *, P < 0.05 vs. perfusion with medium alone; **, P < 0.05 vs. Ang-(1–7).

 


View larger version (16K):
[in this window]
[in a new window]
  		Figure 5. Effects of Ang-(1–7) (A) and Ang II (B) on progesterone production by perfused rat ovary. Ovaries of immature rats pretreated 48 h before with eCG (20 IU) were perfused with medium alone, 1 µM Ang-(1–7), 1 µM Ang II, or a combination of Ang-(1–7) and A-779 (A) or Ang II and A-779 (B). Data points show the mean ± SEM of five to seven ovary perfusions. *, P < 0.05 vs. perfusion with medium alone; **, P < 0.05 vs. Ang-(1–7) or Ang II.

 
A-779, the specific antagonist of Ang-(1–7), completely blocked the estradiol production induced by Ang-(1–7) during the first 4 h of perfusion and blunted it after 6 h (Fig. 4AGo). A-779 alone inhibited estradiol production in three of five ovaries (n = 5; data not shown) compared with the control ovaries, but the results did not reach statistical significance.

A-779 also blocked the effect of Ang-(1–7) on progesterone production (Fig. 5AGo). A significant decrease in progesterone production was observed in A-779-perfused ovaries compared with controls (P < 0.05; data not shown).

To verify whether the effect of Ang II on steroidogenesis was due to its conversion to Ang-(1–7), ovaries were perfused with a combination of Ang II and A-779. No inhibition of estradiol production was observed (Fig. 4BGo), indicating that the two peptides act through different receptors. However, A-779 blocked the progesterone production induced by Ang II (Fig. 5BGo), indicating that Ang-(1–7) could be involved in this response.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The present study provides the first evidence that Ang-(1–7), a biologically active member of the RAS, is present in the rat ovary and that its level varies during the estrous cycle. Ovarian Ang-(1–7) levels are maximal at proestrus and estrus, and Ang-(1–7) induces estradiol production, an effect that is blocked by its specific antagonist, A-779. These findings raise the possibility that Ang-(1–7) plays a role in preovulatory and immediate postovulatory events.

The ovarian concentrations of Ang-(1–7) at proestrus and estrus and in eCG-treated immature rats were higher than the plasma concentrations determined in our laboratory for male Wistar rats (21, 22) and were also higher than those in other organs, such as heart, kidney, and adrenal, of female Sprague Dawley rats (25). Senanayake and co-workers (25) demonstrated that plasma Ang-(1–7) increased during proestrus, but the circulating levels of Ang II were unaffected by the estrous cycle. Ang-(1–7) can be formed from Ang II by Ang II hydrolysis by prolyl-endopeptidase (PEP) or prolyl-carboxypeptidades or directly from Ang I by NEP 24.11 or PEP (16). To our knowledge, the presence of NEP in the rat ovary has not been demonstrated. However, in the uterus the level of NEP is increased by progesterone and decreased by estrogen (26). Considering the high levels of estrogen production in the proestrous ovary, NEP does not seem to be involved in the increase in Ang-(1–7) observed in proestrus. On the other hand, the levels of PEP in mouse ovaries were observed to be higher in estrus and lower in diestrus (27). Therefore, it is likely that PEP, rather than NEP, would be involved in the increase in Ang-(1–7) observed in proestrus and estrus and in eCG-treated rats. In addition, the possible involvement of the Ang-(1–7)-forming enzyme, ACE-2 (17), should be considered.

In this study we found the ovarian Ang II concentration to be more than 10-fold higher in proestrus than in any other phase of the estrous cycle. Also, these levels were higher than the plasma concentrations found in male Wistar rats (21, 22) and even higher than those observed in female Sprague Dawley rats (25). Husain et al. (28) also demonstrated that the levels of Ang II-ir were 8- to 65-fold higher in the rat ovary than in plasma. These levels were not changed by bilateral nephrectomy, indicating that ovarian Ang II content is not due to a simple contamination of this tissue with circulating Ang II. The possibility that the Ang II present in the ovary only represents the peptide sequestered by ovarian Ang II receptors was excluded by studies showing that, in addition to prorenin, renin, and ACE, angiotensinogen is present in the ovary (29). The demonstration of angiotensinogen mRNA in the ovary (30) provided further evidence to exclude the possibility that Ang II-ir in the ovary is merely derived from the bloodstream.

The angiogenic actions of Ang II have been demonstrated (31), and the high levels observed in the present study during proestrus could be involved in the vascular proliferation observed in this phase of the estrous cycle. Ang-(1–7), on the other hand, has been demonstrated to have antiproliferative and antiangiogenic effects (32, 33). Therefore, the differential presence of both peptides, Ang II present in proestrus and Ang-(1–7) in proestrus and estrus, could be part of a coordinated array of proliferative events that occurs during pre- and postovulatory phases of the estrous cycle.

Ang II is very well known for its vasoconstrictor action. However, no ovarian vasoconstriction is observed after Ang II treatment. Instead, vasodilatation was observed in rabbit ovaries perfused in vitro with Ang II (34). Although this effect could be accounted for by prostaglandin release induced by Ang II, other contraregulatory factors, such as natriuretic peptides, that usually play a role opposite that of the RAS as systemic regulators of blood pressure and fluid homeostasis cannot be discounted. The presence of natriuretic peptides, atrial natriuretic peptide and C-type natriuretic peptide, has been demonstrated in rat ovaries as well as their fluctuations throughout the estrous cycle; they reach a peak around midcycle at the time of ovulation (35, 36, 37). In addition, Ang-(1–7), instead of being a vasoconstrictor like Ang II, has been demonstrated in different species and preparations to have vasodilator properties (16) and could be another factor involved in the vasodilatation reported in the proestrus ovary.

In the present study, we used a well characterized model for in vitro perfusion of preovulatory rat ovaries using a medium devoid of any circulating factors that could interfere with estradiol production to examine the effects of angiotensins on steroidogenesis. Both Ang-(1–7) and Ang II significantly stimulated the production of estradiol and progesterone. Ang II has been shown to stimulate estradiol production in different species and preparations (10, 38, 39, 40, 41). The effect of Ang II on progesterone production is somewhat controversial. No effect was observed by others (38) in eCG-treated rats, probably because they used a shorter incubation time (3 h) than we did. In human granulosa cultured cells, both inhibitory and stimulatory effects of Ang II were observed depending on the time of culture, and these actions seemed to be mediated by AT2 receptors (41).

The observation that Ang II stimulates estradiol production is consistent with the localization of Ang II receptors on the granulosa cells of the developing ovarian follicles (42). Ovarian follicular estrogen levels are of fundamental importance in the selection and maintenance of dominant follicles (43, 44). The presence of Ang II receptors on the developing follicles in the ovary (28), together with the selective effects of Ang II on estrogen secretion, suggests a role for Ang II in maintaining intrafollicular estrogen levels during follicular maturation. The signal transduction mechanism coupled to the steroidogenic effect of Ang II is not clear. However, in granulosa cells from hypophysectomized, diethylstilbestrol-treated rats, Ang II had no effect on basal or stimulated phosphoinositide turnover, intracellular calcium levels, or cAMP production (45).

The effect of Ang-(1–7) on the production of estradiol and progesterone was as potent as that of Ang II. This effect was blocked by A-779, a selective antagonist, indicating that a specific Ang-(1–7) receptor is involved in this response. To our knowledge, this is the first demonstration of a steroidogenic effect of Ang-(1–7). The inhibition of basal progesterone production by A-779 seems to indicate an action of endogenous Ang-(1–7). In contrast to Ang II, which has been extensively studied, the localization of Ang-(1–7) in the ovary has not been described. We did not investigate the signal transduction mechanism coupled to the steroidogenic action of Ang-(1–7). It has been shown that Ang-(1–7) stimulates the release of prostaglandins from porcine aortic endothelial cells as well as vascular smooth muscle cells (46, 47). Prostaglandins are involved in the ovulation induced by the increase in Ang II concomitantly with estradiol production (10). Thus, it is likely that prostaglandins may be involved in the effects of ovarian RAS in the maintenance of intrafollicular estrogen levels in the preovulatory follicles.

As Ang-(1–7) and Ang II had similar effects on estradiol and progesterone production, the effect of Ang II could be due to its conversion to Ang-(1–7). Ovary perfusion using a combination of Ang II and A-779 resulted in no inhibition of estradiol production. This result indicates that the two peptides must be acting through different receptors: Ang-(1–7) receptors antagonized by A-779 and Ang II receptors not antagonized by A-779. On the other hand, the effect of Ang II on progesterone production was blocked by A-779. Therefore, it seems that the effect of Ang II is due to its conversion to Ang-(1–7). The localization, mechanism of action, and other roles of Ang-(1–7) in the ovarian physiology remain to be determined, but it seems likely that Ang II and Ang-(1–7) could play complementary roles.

It has been recently reported that female mice lacking angiotensinogen have normal fertility (48). This is not surprising considering that the development of ovarian follicles is regulated by a vast array of hormones and growth factors, but the key role in the process is played by gonadotropins and gonadal steroids. Thus, RAS could be considered one of the modulators of ovarian physiology. However, as serious disturbances of the reproductive process, such as polycystic ovary syndrome and ovarian hyperstimulation syndrome, have been associated with aberrations of RAS (4, 5, 6, 7), this modulatory role seems to be very important.

In summary, the present results indicate that Ang-(1–7) may play a role in pre- and postovulatory events. To our knowledge, this is the first report showing that Ang-(1–7) is produced in a cyclic manner and has a physiological role in the ovary.


   Acknowledgments
 
We thank Jacqueline Braga Pereira for her expert assistance with the RIA, and Drs. Jose Antunes Rodrigues and Ana Lucia V. Favaretto for their generous gift of the RIA antibodies. We also thank Dr. Fernando M. Reis for carefully reading the manuscript.


   Footnotes
 
This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnólogico, Fapemig, and Pronex. Presented in part at the 82nd Annual Meeting of The Endocrine Society, Toronto, Canada, 2000.

1 A.P.R.C. is the recipient of a Coordenação de Aperfeiçoamento de Pessoal de Nível Superior scholarship. Back

2 Present address for A.P.R.C.: Department of Morphophysiology, Federal University of Piaui, Teresina, 64049-550. Back

Abbreviations: ACE, Angiotensin-converting enzyme; Ang, angiotensin; eCG, equine chorionic gonadotropin; hCG, human chorionic gonadotropin; -ir, immunoreactivity; NEP, neutral endopeptidase 24.11; PEP, prolyl-endopeptidase; RAS, renin-angiotensin system.

Received October 25, 2002.

Accepted for publication January 28, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Yoshimura Y 1997 The ovarian renin-angiotensin system in reproductive physiology. Front Neuroendocrinol 18:247–291[CrossRef][Medline]
  2. Mukhopadhyay AK, Holstein K, Szkudlinski M, Brunswig-Spickenheier B, Leidenberger FA 1991 The relationship between prorenin levels in follicular fluid and follicular atresia in bovine ovaries. Endocrinology 129:2367–2375[Abstract/Free Full Text]
  3. Palumbo A, Jones C, Lightman A, Carcangiu ML, DeCherney AH, Naftolin F 1989 Immunohistochemical localization of renin and angiotensin II in human ovaries. J Obstet Gynecol 160:8–14
  4. Palumbo A, Pourmotabbed G, Carcangiu ML, Androbe-Gordon P, Rosa L, DeCherney A, Naftolin F 1993 Immunohistochemical localization of renin and angiotensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertil Steril 60:280–284[Medline]
  5. Jaatinen FA, Matinlauri I, Anttila L, Koskinen P, Erkkola R, Irjala K 1995 Serum total renin is elevated in women with polycystic ovarian syndrome. Fertil Steril 63:1000–1004[Medline]
  6. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, Schenker JG 1987 Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48:57–61[Medline]
  7. Ong ACM, Eisen V, Rennie DP, Homburg R, Lachelin GCL, Jacobs HS, Slater JDH 1991 The pathogenesis of the ovarian hyperstimulation syndrome (OHS): s possible role for ovarian renin. Clin Endocrinol (Oxf) 34:43–49[Medline]
  8. Pellicer A, Palumbo A, DeCherney AH, Naftolin F 1988 Blockade of ovulation by an angiotensin antagonist. Science 240:1660–1661[Abstract/Free Full Text]
  9. Yoshimura Y, Karube M, Koyama N, Shiokawa S, Nanno T, Nakamura Y 1992 Angiotensin II directly induces follicle rupture and oocyte maturation in the rabbit. FEBS Lett 307:305–308[CrossRef][Medline]
  10. Yoshimura Y, Karube M, Oda T, Koyama N, Shiokawa S, Akiba M, Yoshinaga A, Nakamura Y 1993 Locally produced angiotensin II induces ovulation by stimulating prostaglandin production in in vitro perfused rabbit ovaries. Endocrinology 133:1609–1616[Abstract/Free Full Text]
  11. Daud AI, Bumpus FM, Husain A 1988 Evidence for selective expression of angiotensin II receptors on atretic follicles in the rat ovary: an autoradiographic study. Endocrinology 122:2727–2734[Abstract/Free Full Text]
  12. Daud AI, Bumpus FM, Husain A 1989 Angiotensin II: does it have a direct obligate role in ovulation? Science 245:870–871[Free Full Text]
  13. Daud AI, Bumpus FM, Husain A 1990 Characterization of angiotensin I-converting enzyme (ACE)-containing follicles in the rat ovary during the estrous cycle and effects of ACE inhibitor on ovulation. Endocrinology 126:2927–2935[Abstract/Free Full Text]
  14. Peterson CM, Morioka N, Zhu C, Ryan JW, Le Maire WJ 1993 Angiotensin-converting enzyme inhibitors have no effect on ovulation and ovarian steroidogenesis in the perfused rat ovary. Reprod Toxicol 7:131–135[CrossRef][Medline]
  15. Yoshimura Y, Koiama N, Karube M, Oda T, Akiba M, Yoshinaga A, Shiokawa S, Jinno M, Nakamura Y 1994 Gonadotropin stimulates ovarian renin-angiotensin system in the rabbit. J Clin Invest 93:180–187
  16. Santos RAS, Campagnole-Santos MJ, Andrade SP 2000 Angiotensin-(1–7): an update. Regul Pept 91:45–62[CrossRef][Medline]
  17. Santos RAS, Passaglio KT, Pesquero JB, Bader M, Silva ACS 2001. Interactions between angiotensin-(1–7), kininins and angiotensin II in kidney and blood vessels. Hypertension 38:660–664
  18. Santos RAS, Campagnole-Santos MJ, Baracho NCV, Fontes MAP, Silva LCS, Neves LAA, Oliveira BR, Caligiorne SM, Rodrigues ARV, Gropen Jr C, Carvalho DS, Khosla WC 1994 Characterization of a new angiotensin antagonist selective for angiotensin-(1–7): evidence that the actions of angiotensin-(1–7) are mediated by specific angiotensin receptors. Brain Res Bull 35:293–298[CrossRef][Medline]
  19. Neves LAA, Almeida AP, Khosla MC, Santos RAS 1995 Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Biochem Pharmacol 50:1451–1459[CrossRef][Medline]
  20. Chappell MC, Brosnihan KB, Diz DI, Ferrario CM 1989 Identification of angiotensin-(1–7) in rat brain. Evidence for differential processing of angiotensin peptides. J Biol Chem 264:16518–16523[Abstract/Free Full Text]
  21. Botelho LMO, Block CH, Khosla MC, Santos RAS 1994 Plasma angiotensin-(1–7) immunoreactivity is increased by salt load, water deprivation and hemorrhage. Peptides 15:723–729[CrossRef][Medline]
  22. Fagundes-Moura CR 1997 Perfil plasmático de angiotensinas durante o desenvolvimento da hipertensão renal tipo um-rim um clip em ratos. Efeito do tratamento com losartan. Universidade Federal de Minas Gerais, Thesis
  23. Koos RD, Jaccarino FJ, Magaril RA, Le Maire WJ 1984 Perfusion of the rat ovary in vitro: methodology, induction of ovulation, and pattern of steroidogenesis. Biol Reprod 30:1135–1141[Abstract]
  24. Brännström M 1993 In vitro perfused rat ovary. In: Heindel JJ, ed. Female reproductive toxicology. San Diego: Academic Press; 160–169
  25. Senanayake PS, Smeby RR, Martins AS, Moriguchi A, Kumagai H, Ganten D, Brosnihan KB 1998 Adrenal, kidney, and heart angiotensins in female murine Ren-2 transfected hypertensive rats. Peptides 19:1685–1694[CrossRef][Medline]
  26. Pinto FM, Armesto CP, Magraner J, Trujillo M, Martin JD, Cadenas ML 1999 Tachykinin receptor and neutral endopeptidase gene expression in the rat uterus: characterization and regulation in response to ovarian steroid treatment. Endocrinology 140:2526–2532[Abstract/Free Full Text]
  27. Ohta N, Takahashi T, Mori T, Park MK, Kawashima S, Takahashi K, Kobayashi H 1992 Hormonal modulation of prolyl endopeptidase and dipeptidyl peptidase IV activities in the mouse uterus and ovaries. Acta Endocrinol (Copenh) 127:262–266
  28. Husain A, Bumpus FM, DeSilva P, Speth RC 1987 Localization of angiotensin II receptors in ovarian follicles and the identification of angiotensin II in the rat ovaries. Proc Natl Acad Sci USA 84:2489–2493[Abstract/Free Full Text]
  29. Thomas WG, Sernia C 1990 The immunocytochemical localization of angiotensinogen in the rat ovary. Cell Tissue Res 261:367–373[CrossRef][Medline]
  30. Ohkubo H, Nakayama K, Tanaka T, Nakamishi S 1986 Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity. J Biol Chem 261:319–323[Abstract/Free Full Text]
  31. Fernandez LA, Twickler J, Mead A 1985 Neovascularization produced by angiotensin II. J Lab Clin Med 105:141–145[Medline]
  32. Machado RDP, Santos RAS, Andrade SP 1999 Opposing actions of angiotensins on angiogenesis. Life Sci 66:67–76
  33. Machado RDP, Santos RAS, Andrade SP 2001 Mechanism of angiotensin-(1–7)-induced inhibition of angiogenesis. Am J Physiol 280:R994–R1000
  34. Kuo TC, Endo K, Dharmarajan AM, Miyazaki T, Atlas SJ, Wallach EE 1991 Direct effect of angiotensin II on in vitro perfused rabbit ovary. J Reprod Fertil 92:469–474[Abstract/Free Full Text]
  35. Gutkowska J, Tremblay J, Antakly T, Meyer R, Mukaddam-Daher S, Nemer M 1993 The atrial natriuretic peptide system in the rat ovaries. Endocrinology 132:693–700[Abstract/Free Full Text]
  36. Jankowski M, Reis AM, Mukaddam-Daher S, Dam T-V, Farookhi R, Gutkowska J 1997 C-Type natriuretic peptide and guanylyl cyclase receptors in the rat ovary are modulated by the estrous cycle. Biol Reprod 56:59–66[Abstract]
  37. Gutkowska J, Jankowski M, Sairam MR, Fujio N, Reis AM, Mukaddam-Daher S, Tremblay J 1999 Hormonal regulation of natriuretic peptide system during induced follicular development in the rat. Biol Reprod 61:162–170[Abstract/Free Full Text]
  38. Pucell AG, Bumpus FM, Husain A 1987 Rat ovarian angiotensin II receptors: characterization and coupling to estrogen secretion. J Biol Chem 262:7076–7080[Abstract/Free Full Text]
  39. Bumpus FM, Pucell AG, Daud AI, Husain A 1988 Angiotensin II: an intraovarian regulatory peptide. Am J Med Sci 295:406–408[Medline]
  40. Aguillera G, Millan MA, Harwood JP 1989 Angiotensin II receptors in the gonads. Am J Hypertension 2:395–402[Medline]
  41. Johnson MC, Vega M, Vantman D, Troncoso JL, Devoto L 1997 Regulatory role of angiotensin II on progesterone production by cultured human granulosa cells. Expression of angiotensin II type-2 receptor. Mol Hum Reprod 3:663–668[Abstract/Free Full Text]
  42. Speth RC, Husain A 1988 Distribution of angiotensin-converting enzyme and Angiotensin II-receptor binding sites in the rat ovary. Biol Reprod 38:695–702[Abstract]
  43. Hsueh AJW, Adashi EY, Jones PBC, Welsh TH 1984 Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr Rev 5:76–127[Abstract/Free Full Text]
  44. Irianni F, Hodgen GD 1992 Mechanism of ovulation. Endocrinol Metab Clin North Am 21:19–38[Medline]
  45. Pucell AG, Hodges JC, Sen I, Bumpus FM, Husain A 1991 Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology 128:1947–1959[Abstract/Free Full Text]
  46. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM 1992 Stimulation of endothelial cell prostaglandin production by angiotensin peptides: characterization of receptors. Hypertension 19(Suppl II):II.49–II.55
  47. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, Ferrario CM 1993 Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther 265:664–673[Abstract/Free Full Text]
  48. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K-i, Fikamizu A, Murakami K 1994 Angiotensin-deficient mice with hypotension. J Biol Chem 269:31334–31337[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Exp PhysiolHome page
H. Ji, S. Menini, W. Zheng, C. Pesce, X. Wu, and K. Sandberg
Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17{beta}-oestradiol regulation of renal pathology in renal wrap hypertension in rats
Exp Physiol, May 1, 2008; 93(5): 648 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. A. A. Neves, K. Stovall, J. Joyner, G. Valdes, P. E. Gallagher, C. M. Ferrario, D. C. Merrill, and K. B. Brosnihan
ACE2 and ANG-(1-7) in the rat uterus during early and late gestation
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R151 - R161.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. A. Botelho-Santos, W. O. Sampaio, T. L. Reudelhuber, M. Bader, M. J. Campagnole-Santos, and R. A. Souza dos Santos
Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2485 - H2490.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. R. Pepperell, G. Nemeth, Y. Yamada, F. Naftolin, and M. Merino
Localized accumulation of angiotensin II and production of angiotensin-(1-7) in rat luteal cells and effects on steroidogenesis
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E221 - E233.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ferrario, A. J. Trask, and J. A. Jessup
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costa, A. P. R.
Right arrow Articles by Dos Reis, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costa, A. P. R.
Right arrow Articles by Dos Reis, A. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals